Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Cell and gene therapies represent both sides of modern healthcare — the hopeful and the concerning. They advance the science of medicine, treating and curing diseases that we struggled to address in the past.

Director, Marsh & McLennan Advantage, Healthcare
Pharmacy Clinical Director of Marsh McLennan Agency
Senior Vice President at Guy Carpenter
National Practice Leader at Marsh McLennan Agency

Some therapeutic sectors saw their compound annual growth rate drop 10% or more, deviating from long-term trends. Sales should return to normal growth trajectories as backlogs in procedures continue to clear out.

Partner, Health and Life Sciences, Oliver Wyman

Merck executives share their strategy for embedding health equity across the pharma value chain.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Oliver Wyman
Associate Vice President for Health Equity and Lead, Merck for Mothers
Former Executive Director of Health Equity, Merck

As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?

President and CEO, COTA, Inc.

Overheard at the J.P. Morgan Healthcare Conference

Executives detailed plans to take on more risk, build on advances in life sciences, and expressed optimism in Medicare Advantage, despite missing enrollment targets.

Insights in your inbox

Subscribe

Pharmaceutical giants are shedding business units with an eye toward focusing on their innovative pharma operations and targeted therapeutic areas.

Head of UK and Ireland Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Life sciences companies need to be more engaged in building partnerships that promote high-value care.

Global Leader, Health and Life Sciences, Oliver Wyman
Life Sciences Business Leader, Huron

Imagine a future where leveraging our DNA and what we know about it prevents illness and improves care outcomes.

Co-Founder and CEO, Genome Medical, and 2020 Tom Main Health Innovation Mentorship Winner

And How Stakeholders Can, Literally, Save the World

Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.

Director, Marsh & McLennan Advantage Insights
Partner, Health and Life Sciences, Oliver Wyman

New Predictions on COVID-19 Vaccines and Herd Immunity

How COVID-19 case counts and vaccines may get us back to normalcy by June.

Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe